Harnessing the power of cytokines to restore immune function

OUR FOCUS

Brooklyn ImmunoTherapeutics is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.

Our most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

LATEST NEWS

2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

[ READ MORE ]

Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

[ READ MORE ]

New clinical trials to investigate combination immunotherapy for treating advanced cancers

[ READ MORE ]